OpenEvidence Raises $210M, Launches Free AI Agent for Physicians

OpenEvidence, the leading medical search and AI application among verified U.S. clinicians, has raised $210M in Series B funding, valuing the company at $3.5 billion. The round was co-led by Google Ventures and Kleiner Perkins, with follow-on investment from Series A leader Sequoia Capital and additional participation from Coatue, Conviction, and Thrive, bringing the company's total funding to over $300M.

The funding announcement coincides with the wide release of OpenEvidence DeepConsult™, described as the first AI agent purpose-built for physicians. This new offering provides every physician with access to PhD-level, medically-specialized AI agents capable of conducting advanced medical research autonomously, analyzing and cross-referencing hundreds of peer-reviewed medical studies in parallel.

OpenEvidence addresses a critical challenge in healthcare: information overload. With medical research volume doubling every five years, clinicians struggle with traditional databases that are slow, fragmented, and require extensive manual searching. The platform allows clinicians to "search once, skip the scavenger hunt, and surface the science in seconds," providing point-of-care answers grounded in the latest research through strategic content partnerships with institutions including the American Medical Association (JAMA) and The New England Journal of Medicine.

The company's growth trajectory has been remarkable. Currently active across more than 10,000 hospitals and medical centers nationwide, OpenEvidence is used by over 40% of physicians in the United States who log in daily, with approximately 65,000 new verified U.S. clinician registrations each month. The platform's usage has exploded from 358,000 logged-in, verified U.S. physician consultations in July 2024 to handling that many consultations each workday—now supporting over 8.5 million clinical consultations by logged-in, verified U.S. physicians per month, representing a 2,000%+ year-over-year growth rate.

DeepConsult represents a significant advancement in medical AI capabilities. While OpenEvidence's core search product focuses on delivering answers within 5-10 seconds, DeepConsult addresses more complex clinical questions, producing comprehensive research reports that would typically take human researchers months to compile for a single topic. Despite requiring over 100 times the compute and cost of a standard search, OpenEvidence is offering DeepConsult entirely free to all verified U.S. clinicians, regardless of their institution or workplace.

Founded by Harvard- and MIT-trained PhDs Daniel Nadler and Zachary Ziegler, OpenEvidence plans to use the new funding to expand strategic content partnerships and enhance its library of advanced medical knowledge. Nadler, who previously founded Kensho (acquired by S&P Global for $700 million in 2018), was recently named to the TIME100 Health list of the 100 Most Influential People in global health in 2025.

Robert M. Wachter, MD, Chair of Medicine at UCSF, praised the company's partnership with the American Medical Association as "a significant step towards fulfilling the promise of trusted, evidence-based clinical decision support." With more than 100 million Americans expected to be treated this year by a doctor who used OpenEvidence, the platform is rapidly becoming integral to modern clinical practice.

Click here for the original news story.